Showing 4611-4620 of 8214 results for "".
- Journey Medical to Acquire Dermira's Qbrexzahttps://practicaldermatology.com/news/journey-medical-to-acquire-dermiras-qbrexza/2460731/Journey Medical Corporation, a partner company of Fortress Biotech, Inc., has entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the US from Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company. The transaction is expected to close early in the secon
- AAD Honors Dr. Ginette Okoye with National Patient Care Hero Award for COVID-19 Testing Workhttps://practicaldermatology.com/news/aad-honors-dr-ginette-okoye-with-national-patient-care-hero-award-for-covid-19-testing-work/2460729/The American Academy of Dermatology (AAD) named board-certified dermatologist Ginette Okoye, MD, FAAD a Patient Care Hero for establishing a dedicated COVID-19 community testing site in a historically underserved neighborhood in northeast Washington, DC. Amid the initial surge in COVID-
- Sincerus Completes Financing With SWK To Support Demand For Customized Dermatologic Medicineshttps://practicaldermatology.com/news/sincerus-completes-financing-with-swk-to-support-demand-for-customized-dermatologic-medicines/2460727/Sincerus Pharmaceuticals, the parent company of Prescriber's Choice and Sincerus Florida, completed a major new round of growth financing with SWK Holdings Corporation, representing the largest investment into the company to date. Use of proceeds will include the build-out and expansion of a
- Dermata Doses First Patient in Phase 1b Trial of Topical DMT310 for Mild-to-Moderate Psoriasishttps://practicaldermatology.com/news/dermata-doses-first-patient-in-phase-1b-trial-of-topical-dmt310-for-mild-to-moderate-psoriasis/2460726/Dermata Therapeutics, Inc. dosed its first patient in a Phase 1b trial of DMT310 for the treatment of mild-to-moderate psoriasis. DMT310 is currently being investigated to treat multiple inflammatory skin diseases. It consists of a once-weekly topical treatment with both mech
- Two-Year Data Confirm Benefits, Safety of Tremfya in PsA and PsOhttps://practicaldermatology.com/news/two-year-data-confirm-benefits-safety-of-tremfya-is-psa-and-pso/2460722/Long-term data from the Phase 3 DISCOVER-2 study show continued benefit for Tremfya (guselkumab) for up to two years in adults with active psoriatic arthritis. Previous data demonstrated skin clearance, joint symptom relief, and safety for Tremfya through 24 weeks and one year (Week 52) in a
- Dr. Roy Geronemus Named CEO of NavaDermhttps://practicaldermatology.com/news/dr-roy-geronemus-named-ceo-of-navaderm/2460715/New York City dermatologist Roy Geronemus, MD is NavaDerm Partners’ new Chief Executive Officer. Dr. Geronemus graduated from Harvard University and pursued his medical education at the University of Miami School of Medicine where he is a member of the school's Alumni Hal
- With Pfizer Grant, GW Dermatology to Expand Telederm for Eczemahttps://practicaldermatology.com/news/with-pfizer-grant-gw-dermatology-to-expand-telederm-for-eczema/2460714/The George Washington University (GW) Department of Dermatology will use a $250,000 grant from Pfizer to expand accessible teledermatology for atopic dermatitis patients in Washington, DC. The dermatology team at GW, led by
- Eirion Therapeutics Closes $40M Series A Investment and Licensing Deal with Shanghai Haohai Biological Technologyhttps://practicaldermatology.com/news/eirion-therapeutics-closes-40m-series-a-investment-and-licensing-deal-with-shanghai-haohai-biological-technology/2460712/Eirion Therapeutics, Inc. closed a $40 million Series A investment and licensing deal with Shanghai Haohai Biological Technology Ltd. The deal will result in a $32 million Series A Preferred Stock investment into Eirion along with exclusive licenses that will be for all of Eir
- Project IMPACT from VisualDX Aims to Reduce Disparities in Medicinehttps://practicaldermatology.com/news/project-impact-from-visualdx-aims-reduce-disparities-in-medicine/2460704/VisualDX is launching Project IMPACT (Improving Medicine’s Power to Address Care and Treatment), a global effort to reduce disparities in medicine and highlight ways to bridge gaps of knowledge and improve healthcare outcomes for patients of color. Inaugural members include thought leaders
- Five-Year Data for Ilumya Show Long-term Efficacy, Safetyhttps://practicaldermatology.com/news/five-year-data-for-ilumya-show-long-term-efficacy-safety/2460698/Long-term data from Phase 3 extension trials for Sun Pharma’s Ilumya (tildrakizumab) in psoriasis show the treatment provided sustained disease control over five years among subjects who were week 28 tildrakizumab responders and etanercept partial responders/nonresponders.